SCHEMBL21591738

SCHEMBL21591738

COc1cc(C(C)OS(C)(=O)=O)c(CCNC(=O)OC(C)(C)C)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.40
MTNR1B P49286 3/20 0.38
MTNR1A P48039 2/20 0.38
DYRK1A Q13627 1/20 0.37
CA1 P00915 6/20 0.36
CA2 P00918 6/20 0.36
ALDH1A1 P00352 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
AAK1 Q2M2I8 1/20 0.35
TP53 P04637 1/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
XBP1 P17861 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CA12 O43570 5/20 0.35
CA9 Q16790 5/20 0.35
GFER P55789 1/20 0.35
IDO1 P14902 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21594070 0.85 MTNR1B (0.42) NQO2MTNR1BMTNR1ADYRK1AALDH1A1
SCHEMBL31569050 0.81 IDO1 (0.44) NQO2CA1CA2ALDH1A1HTT
SCHEMBL23854682 0.80 MTNR1B (0.45) NQO2MTNR1BMTNR1AALDH1A1HTT
SCHEMBL21591739 0.80 MTNR1B (0.41) NQO2MTNR1BMTNR1ADYRK1ACA1
SCHEMBL21594080 0.78 MTNR1A (0.36) NQO2MTNR1BMTNR1ADYRK1AALDH1A1
SCHEMBL29872603 0.78 MTNR1A (0.36) NQO2MTNR1BMTNR1ADYRK1AALDH1A1
SCHEMBL21591747 0.76 MTNR1B (0.46) NQO2MTNR1BMTNR1ADYRK1AALDH1A1
SCHEMBL21327200 0.75 TRPV1 (0.35) MTNR1BMTNR1ADYRK1ACA1CA2
SCHEMBL23854684 0.75 MTNR1B (0.46) NQO2MTNR1BMTNR1ACA1CA2
SCHEMBL28517134 0.75 MTNR1A (0.41) NQO2MTNR1BMTNR1ADYRK1ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713327-B2 Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2023-08-01 US disclosed
US-11713327-B2 Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2023-08-01 US disclosed
EP-4061816-A1 HYDRO-1H-PYRROLO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2022-09-28 EP disclosed
US-20210300947-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-09-30 US disclosed
EP-3807270-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-04-21 EP disclosed
WO-2019238616-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2019-12-19 WO disclosed
WO-2019238616-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713327-B2 Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease SSB, UACA, HLA-DRB1 NQO2 211/4885MTNR1B 2298/4885MTNR1A 2976/4885
US-20210300947-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE SSB, UACA, HLA-DRB1 NQO2 292/4885MTNR1B 2640/4885MTNR1A 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.